TREACE MEDICAL CONCEPTS INC (TMCI) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:TMCI • US89455T1097

2.09 USD
-0.17 (-7.52%)
At close: Feb 3, 2026
2.1 USD
+0.01 (+0.48%)
After Hours: 2/3/2026, 8:00:02 PM
Fundamental Rating

3

TMCI gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 186 industry peers in the Health Care Equipment & Supplies industry. TMCI has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, TMCI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • TMCI had negative earnings in the past year.
  • TMCI had a negative operating cash flow in the past year.
  • In the past 5 years TMCI always reported negative net income.
  • In the past 5 years TMCI always reported negative operating cash flow.
TMCI Yearly Net Income VS EBIT VS OCF VS FCFTMCI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M -50M

1.2 Ratios

  • TMCI's Return On Assets of -25.49% is in line compared to the rest of the industry. TMCI outperforms 47.31% of its industry peers.
  • With a Return On Equity value of -56.18%, TMCI perfoms like the industry average, outperforming 48.92% of the companies in the same industry.
Industry RankSector Rank
ROA -25.49%
ROE -56.18%
ROIC N/A
ROA(3y)-24.09%
ROA(5y)-19.45%
ROE(3y)-52.01%
ROE(5y)-143.15%
ROIC(3y)N/A
ROIC(5y)N/A
TMCI Yearly ROA, ROE, ROICTMCI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400 -500

1.3 Margins

  • TMCI's Gross Margin of 79.87% is amongst the best of the industry. TMCI outperforms 93.01% of its industry peers.
  • TMCI's Gross Margin has been stable in the last couple of years.
  • TMCI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 79.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.08%
TMCI Yearly Profit, Operating, Gross MarginsTMCI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

3

2. Health

2.1 Basic Checks

  • TMCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for TMCI has been increased compared to 1 year ago.
  • TMCI has more shares outstanding than it did 5 years ago.
  • TMCI has a worse debt/assets ratio than last year.
TMCI Yearly Shares OutstandingTMCI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
TMCI Yearly Total Debt VS Total AssetsTMCI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • TMCI has an Altman-Z score of -0.01. This is a bad value and indicates that TMCI is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of TMCI (-0.01) is comparable to the rest of the industry.
  • TMCI has a Debt/Equity ratio of 0.62. This is a neutral value indicating TMCI is somewhat dependend on debt financing.
  • TMCI's Debt to Equity ratio of 0.62 is on the low side compared to the rest of the industry. TMCI is outperformed by 63.44% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Altman-Z -0.01
ROIC/WACCN/A
WACC10.7%
TMCI Yearly LT Debt VS Equity VS FCFTMCI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 3.37 indicates that TMCI has no problem at all paying its short term obligations.
  • TMCI has a better Current ratio (3.37) than 61.29% of its industry peers.
  • A Quick Ratio of 2.36 indicates that TMCI has no problem at all paying its short term obligations.
  • With a Quick ratio value of 2.36, TMCI perfoms like the industry average, outperforming 59.68% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.37
Quick Ratio 2.36
TMCI Yearly Current Assets VS Current LiabilitesTMCI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

5

3. Growth

3.1 Past

  • TMCI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.89%, which is quite good.
  • The Revenue has been growing slightly by 7.90% in the past year.
  • The Revenue has been growing by 39.66% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)14.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4%
Revenue 1Y (TTM)7.9%
Revenue growth 3Y30.41%
Revenue growth 5Y39.66%
Sales Q2Q%11.37%

3.2 Future

  • TMCI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.19% yearly.
  • Based on estimates for the next years, TMCI will show a quite strong growth in Revenue. The Revenue will grow by 14.54% on average per year.
EPS Next Y4.7%
EPS Next 2Y-1%
EPS Next 3Y0.29%
EPS Next 5Y14.19%
Revenue Next Year2.04%
Revenue Next 2Y0.97%
Revenue Next 3Y3.56%
Revenue Next 5Y14.54%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
TMCI Yearly Revenue VS EstimatesTMCI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M
TMCI Yearly EPS VS EstimatesTMCI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 -0.2 -0.4 -0.6 -0.8

0

4. Valuation

4.1 Price/Earnings Ratio

  • TMCI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year TMCI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TMCI Price Earnings VS Forward Price EarningsTMCI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TMCI Per share dataTMCI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1%
EPS Next 3Y0.29%

0

5. Dividend

5.1 Amount

  • No dividends for TMCI!.
Industry RankSector Rank
Dividend Yield 0%

TREACE MEDICAL CONCEPTS INC

NASDAQ:TMCI (2/3/2026, 8:00:02 PM)

After market: 2.1 +0.01 (+0.48%)

2.09

-0.17 (-7.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-06
Earnings (Next)02-26
Inst Owners61.21%
Inst Owner Change-1.2%
Ins Owners20.74%
Ins Owner Change-0.95%
Market Cap133.17M
Revenue(TTM)218.88M
Net Income(TTM)-50.11M
Analysts50.91
Price Target4.93 (135.89%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.88%
Min EPS beat(2)4.79%
Max EPS beat(2)8.96%
EPS beat(4)4
Avg EPS beat(4)26.76%
Min EPS beat(4)4.79%
Max EPS beat(4)74.58%
EPS beat(8)7
Avg EPS beat(8)13.87%
EPS beat(12)10
Avg EPS beat(12)14.08%
EPS beat(16)12
Avg EPS beat(16)-130.3%
Revenue beat(2)0
Avg Revenue beat(2)-1.14%
Min Revenue beat(2)-1.26%
Max Revenue beat(2)-1.01%
Revenue beat(4)1
Avg Revenue beat(4)-0.75%
Min Revenue beat(4)-1.26%
Max Revenue beat(4)0.3%
Revenue beat(8)5
Avg Revenue beat(8)0.36%
Revenue beat(12)8
Avg Revenue beat(12)1.09%
Revenue beat(16)12
Avg Revenue beat(16)2.15%
PT rev (1m)-9.37%
PT rev (3m)-44.4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8882.04%
EPS NY rev (1m)0%
EPS NY rev (3m)1.55%
Revenue NQ rev (1m)0.16%
Revenue NQ rev (3m)-20.87%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)-6.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.61
P/FCF N/A
P/OCF N/A
P/B 1.49
P/tB 1.93
EV/EBITDA N/A
EPS(TTM)-0.8
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS3.44
BVpS1.4
TBVpS1.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.49%
ROE -56.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 79.87%
FCFM N/A
ROA(3y)-24.09%
ROA(5y)-19.45%
ROE(3y)-52.01%
ROE(5y)-143.15%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.08%
F-Score3
Asset Turnover1.11
Health
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 141.2%
Cap/Sales 6.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.37
Quick Ratio 2.36
Altman-Z -0.01
F-Score3
WACC10.7%
ROIC/WACCN/A
Cap/Depr(3y)349.5%
Cap/Depr(5y)305.94%
Cap/Sales(3y)7.38%
Cap/Sales(5y)5.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4%
EPS Next Y4.7%
EPS Next 2Y-1%
EPS Next 3Y0.29%
EPS Next 5Y14.19%
Revenue 1Y (TTM)7.9%
Revenue growth 3Y30.41%
Revenue growth 5Y39.66%
Sales Q2Q%11.37%
Revenue Next Year2.04%
Revenue Next 2Y0.97%
Revenue Next 3Y3.56%
Revenue Next 5Y14.54%
EBIT growth 1Y22.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year88.29%
EBIT Next 3Y24.66%
EBIT Next 5Y26.75%
FCF growth 1Y49.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y69.98%
OCF growth 3YN/A
OCF growth 5YN/A

TREACE MEDICAL CONCEPTS INC / TMCI FAQ

Can you provide the ChartMill fundamental rating for TREACE MEDICAL CONCEPTS INC?

ChartMill assigns a fundamental rating of 3 / 10 to TMCI.


What is the valuation status of TREACE MEDICAL CONCEPTS INC (TMCI) stock?

ChartMill assigns a valuation rating of 0 / 10 to TREACE MEDICAL CONCEPTS INC (TMCI). This can be considered as Overvalued.


Can you provide the profitability details for TREACE MEDICAL CONCEPTS INC?

TREACE MEDICAL CONCEPTS INC (TMCI) has a profitability rating of 2 / 10.


What is the earnings growth outlook for TREACE MEDICAL CONCEPTS INC?

The Earnings per Share (EPS) of TREACE MEDICAL CONCEPTS INC (TMCI) is expected to grow by 4.7% in the next year.